BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 18533766)

  • 1. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
    Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.
    Correll CU
    J Clin Psychiatry; 2011 Jan; 72(1):e01. PubMed ID: 21272508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.
    Correll CU
    Int Rev Psychiatry; 2008 Apr; 20(2):195-201. PubMed ID: 18386212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia.
    Correll CU
    J Clin Psychiatry; 2011 Aug; 72(8):e26. PubMed ID: 21899814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of antipsychotics in children and adolescents.
    Findling RL; Steiner H; Weller EB
    J Clin Psychiatry; 2005; 66 Suppl 7():29-40. PubMed ID: 16124839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some adverse effects of antipsychotics: prevention and treatment.
    Lader M
    J Clin Psychiatry; 1999; 60 Suppl 12():18-21. PubMed ID: 10372605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
    Correll CU; Penzner JB; Parikh UH; Mughal T; Javed T; Carbon M; Malhotra AK
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):177-206. PubMed ID: 16321730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
    McConville BJ; Sorter MT
    J Clin Psychiatry; 2004; 65 Suppl 6():20-9. PubMed ID: 15104523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy, safety, and tolerability of antipsychotics in the elderly.
    Maixner SM; Mellow AM; Tandon R
    J Clin Psychiatry; 1999; 60 Suppl 8():29-41. PubMed ID: 10335669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
    Vitiello B; Correll C; van Zwieten-Boot B; Zuddas A; Parellada M; Arango C
    Eur Neuropsychopharmacol; 2009 Sep; 19(9):629-35. PubMed ID: 19467582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
    Zuddas A; Zanni R; Usala T
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of antipsychotic medications.
    Muench J; Hamer AM
    Am Fam Physician; 2010 Mar; 81(5):617-22. PubMed ID: 20187598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risperidone use in child and adolescent psychiatric patients].
    Chevreuil C; Reymann JM; Frémaux T; Polard E; Séveno T; Bentué-Ferrer D
    Therapie; 2008; 63(5):359-75. PubMed ID: 19154706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of atypical antipsychotics in the treatment of autistic disorder.
    Stachnik JM; Nunn-Thompson C
    Ann Pharmacother; 2007 Apr; 41(4):626-34. PubMed ID: 17389666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatments for bipolar disorder: safety and adverse effect profiles.
    Marken PA; Pies RW
    Ann Pharmacother; 2006 Feb; 40(2):276-85. PubMed ID: 16403851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
    Meltzer HY; Davidson M; Glassman AH; Vieweg WV
    J Clin Psychiatry; 2002; 63 Suppl 9():25-9. PubMed ID: 12088173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.